We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




HDL Does Not Always Lower Risk of CV Disease

By LabMedica International staff writers
Posted on 02 Aug 2018
High-density lipoproteins (HDL) are a family of particles found in the blood that vary in sizes and cholesterol contents. More...
HDL has traditionally been measured as the total cholesterol carried by the HDL particles, known as HDL cholesterol.

HDL cholesterol, however, does not necessarily reflect the overall concentration, the uneven distribution, or the content and function of HDL particles. Previous studies have demonstrated the heart-protective features of HDL. This good cholesterol carries fats away from the heart, reducing the build-up of plaque and lowering the potential for cardiovascular disease.

Scientists from the University of Pittsburgh Medical School (Pittsburgh, PA, USA) studied 1,138 women aged 45 through 84 enrolled across the USA in the Multi-Ethnic Study of Atherosclerosis (MESA) that began in 1999 and is still following participants today. The participants mean age was 61.8 ± 10.3; and 61% natural-, 21% surgical-, and 18% peri-menopause.

The team observed that the number and size of the HDL particles and total cholesterol carried by HDL particles. The study also looked at how age when women transitioned into post menopause, and the amount of time since transitioning, may impact the expected cardio-protective associations of HDL measures. The harmful association of higher HDL cholesterol with atherosclerosis risk was most evident in women with older age at menopause and who were greater than, or equal to, 10 years into post menopause.

In contrast to HDL cholesterol, a higher concentration of total HDL particles was associated with lower risk of atherosclerosis. Additionally, having a high number of small HDL particles was found beneficial for postmenopausal women. These findings persist irrespective of age and how long it has been since women became postmenopausal. On the other hand, large HDL particles are linked to an increased risk of cardiovascular disease close to menopause. During this time, the quality of HDL may be reduced, increasing the chance for women to develop atherosclerosis or cardiovascular disease.

The authors concluded that elevated HDL-C may not always be cardioprotective in postmenopausal women. The cardioprotective capacity of large HDL-P may adversely compromise close to menopause supporting the importance of assessing how the menopause transition might impact HDL quality and related cardiovascular disease risk later in life.

Samar R. El Khoudary, PhD, MPH, FAHA, an associate professor and lead author of the study, said, ‘This study confirms our previous work on a different group of women and suggests that clinicians need to take a closer look at the type of HDL in middle-aged and older women, because higher HDL cholesterol may not always be as protective in postmenopausal women as we once thought. High total HDL cholesterol in postmenopausal women could mask a significant heart disease risk that we still need to understand." The study was published on July 19, 2018, in the journal Arteriosclerosis, Thrombosis, and Vascular Biology.

Related Links:
University of Pittsburgh Medical School


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.